Cargando…

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

OBJECTIVE: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gladman, Dafna D, Kavanaugh, Arthur, Gómez-Reino, Juan J, Wollenhaupt, Jürgen, Cutolo, Maurizio, Schett, Georg, Lespessailles, Eric, Guerette, Benoit, Delev, Nikolay, Teng, Lichen, Edwards, Christopher J, Birbara, Charles A, Mease, Philip J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045740/ https://www.ncbi.nlm.nih.gov/pubmed/30018799 http://dx.doi.org/10.1136/rmdopen-2018-000669

Ejemplares similares

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
por: Kavanaugh, Arthur, et al.
Publicado: (2019)

Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis
por: Michelsen, Brigitte, et al.
Publicado: (2017)

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
por: McInnes, Iain B, et al.
Publicado: (2022)

Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
por: Mease, Philip J., et al.
Publicado: (2020)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
por: Kavanaugh, Arthur, et al.
Publicado: (2016)

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
por: Mease, Philip J., et al.
Publicado: (2019)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
por: Mease, Philip J, et al.
Publicado: (2018)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
por: Gladman, D, et al.
Publicado: (2014)

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
por: Mease, P, et al.
Publicado: (2015)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis
por: Dubash, Sayam, et al.
Publicado: (2022)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
por: Strand, Vibeke, et al.
Publicado: (2019)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Multimodal imaging of the distal interphalangeal-joint synovio-entheseal complex in psoriatic arthritis (MIDAS): a cross-sectional study on the diagnostic accuracy of different imaging modalities comparing psoriatic arthritis to psoriasis and osteoarthritis
por: Guldberg-Møller, Jørgen, et al.
Publicado: (2022)

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
por: Gladman, Dafna, et al.
Publicado: (2020)

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2020)

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
por: Mease, Philip J, et al.
Publicado: (2018)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
por: Chandran, Vinod, et al.
Publicado: (2023)

Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study
por: Colaco, Keith, et al.
Publicado: (2022)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies
por: Gladman, Dafna D., et al.
Publicado: (2019)

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study
por: Coates, Laura C., et al.
Publicado: (2021)

Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews
por: Ogdie, Alexis, et al.
Publicado: (2020)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era
por: Haugeberg, Glenn, et al.
Publicado: (2020)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_slrtm49v844h6ertobrlp9kduv